MedTrace Logo

Validation of a Tear-based Screening Assay for Breast Cancer

NCT04928014 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 205

Last updated 2023-07-03

No results posted yet for this study

Summary

This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms. This tear-based screening test was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

Conditions

  • Healthy
  • Breast Cancer
  • Breast Cancer Female
  • Health Care Utilization
  • Health Knowledge, Attitudes, Practice
  • Health Personnel Attitude
  • Health Care Acceptability

Interventions

OTHER

Schirmer Strip

A tear-based screening assay for breast cancer developed and validated by Namida Lab, Inc., a high complexity CLIA-certified lab. It consists of two parts: tear sample collection using a Schirmer Strip and a clinical lab-developed test that measures protein biomarkers for breast cancer screening.

Sponsors & Collaborators

  • Namida Lab

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-12-31
Completion
2025-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04928014 on ClinicalTrials.gov